

# Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain

NCT05909709

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Alimorad Farshchian
Enrollment	15 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- In order to be eligible to participate in this study, all individuals must meet all of the following criteria:
- Subjects age  $\geq$  18 years at the time of signing the Informed Consent Form.
- Male or Female.
- Ability of participant to understand and the willingness to sign a written informed consent document.
- Facetogenic back pain diagnosed using the following diagnostic criteria Subjects who have chronic low back pain based on clinical evaluation. Pain onset at dorsal extension and release at flexion is often considered suggestive for facet pain, even if non-specific, such as maximal tenderness upon deep palpation of posterior elements.

... and 5 more (see full listing online)

### Exclusion (30)

- Previous surgical intervention for back pain
- Previous stem cell injection(s) within the last year
- Use of anticoagulation or NSAIDs within 5 days of the injection
- MRI finding of severe high-grade lumbar stenosis
- Leg pain exceeding back pain

... and 25 more (see full listing online)

## Locations (1 total)

---

The Center for Regenerative Medicine, North Miami, Florida, United States